IL6 and non-small cell lung carcinoma: The data presented here have demonstrated that miR-762 upregulation, which is regulated, at least in part, by IL6/STAT3 signaling pathway, confers acquired resistance to gefitinib in NSCLC cells (Fig. 6e).